Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

New treatment advances for patients with follicular lymphoma

New treatment advances for patients with follicular lymphoma

Herceptin results "quite remarkable"

Herceptin results "quite remarkable"

Hormone responsible for types of high blood pressure could also cause preeclampsia

Hormone responsible for types of high blood pressure could also cause preeclampsia

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

Dengue and other viruses may have developed tricks that let them reproduce inside macrophages

Dengue and other viruses may have developed tricks that let them reproduce inside macrophages

Anti-cancer antibodies produced in chickens

Anti-cancer antibodies produced in chickens

Mutations in the targets of designer drugs critically influence their effectiveness

Mutations in the targets of designer drugs critically influence their effectiveness

New hope for those deaf from immune system attack

New hope for those deaf from immune system attack

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

New discoveries in treatment for patients with non-Hodgkin's lymphoma

New discoveries in treatment for patients with non-Hodgkin's lymphoma

Immunomedics awarded U.S. and Australian patents

Immunomedics awarded U.S. and Australian patents

West Nile virus vaccine may be ready by the end of the year

West Nile virus vaccine may be ready by the end of the year

MabThera highly effective in treating rheumatoid arthritis

MabThera highly effective in treating rheumatoid arthritis

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Zevalin safe and effective for non-Hogdkin's lymphoma patients

Zevalin safe and effective for non-Hogdkin's lymphoma patients

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics announces new patent for Hyperlipidemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.